The U.S. Food and Drug Administration (FDA) recently approved Tyruko (natalizumab-sztn, made by Sandoz, a division of the Novartis group). Tyruko is the first biosimilar disease-modifying therapy (DMT) for individuals…
eMS News is the monthly email newsletter distributed from the Rocky Mountain MS Center. Each issue contains articles and features on the latest developments at the Rocky Mountain MS Center and general MS news from around the world. Regular features include the latest information on current clinical trials and research studies, upcoming events, fundraising activities and more.
Beginning below, you’ll find archives of our eMS News updates all the way back to 2012.
Browse our latest updated, or search below to find the topic you’re looking for.